EP2298808A1 - Antikörper gegen C5 und deren therapeutischen Verwendungen - Google Patents

Antikörper gegen C5 und deren therapeutischen Verwendungen Download PDF

Info

Publication number
EP2298808A1
EP2298808A1 EP10185086A EP10185086A EP2298808A1 EP 2298808 A1 EP2298808 A1 EP 2298808A1 EP 10185086 A EP10185086 A EP 10185086A EP 10185086 A EP10185086 A EP 10185086A EP 2298808 A1 EP2298808 A1 EP 2298808A1
Authority
EP
European Patent Office
Prior art keywords
antibody
amino acid
seq
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10185086A
Other languages
English (en)
French (fr)
Inventor
Mark J. Evans
Louis Matis
Eileen Elliott Mueller
Steven H. Nye
Scott Rollins
Russell P. Rother
Jeremy P. Springhorn
Stephen P. Squinto
Thomas C. Thomas
Yi Wang
James A. Wilkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22888581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2298808(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of EP2298808A1 publication Critical patent/EP2298808A1/de
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • USRDS Renal Data System
  • the USRDS compiles data on kidney disease in the United States in conjunction with the National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases, of the National Institutes of Health (NIDDKD).
  • NIDDKD National Institute of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic, and Hematologic Diseases, of the National Institutes of Health
  • the first domain of each chain is highly variable in amino acid sequence, providing the vast spectrum of antibody binding specificities found in each individual. These are known as variable heavy (VH) and variable light (VL) domains.
  • VH variable heavy
  • VL variable light
  • the second and subsequent (if any) domains of each chain are relatively invariant in amino acid sequence. These are known as constant heavy (CH) and constant light (CL) domains.
  • C3a is an anaphylatoxin (see discussion below).
  • C3b binds to bacterial and other cells, as well as to certain viruses and immune complexes, and tags them for removal from the circulation. (C3b in this role is known as opsonin.)
  • the opsonic function of C3b is considered to be the most important anti-infective action of the complement system. Patients with genetic lesions that block C3b function are prone to infection by a broad variety of pathogenic organisms, while patients with lesions later in the complement cascade sequence, i.e., patients with lesions that block C5 functions, are found to be more prone only to Neisseria infection, and then only somewhat more prone ( Fearon, in Intensive Review of Internal Medicine, 2nd Ed. Fanta and Minaker, eds. Brigham and Women's and Beth Israel Hospitals, 1983 ).
  • endogenous immune complexes The best known example of the formation of endogenous immune complexes is the DNA anti-DNA complexes produced in connection with systemic lupus erythematosus (lupus, SLE).
  • Other important sources of endogenous antigens include malignancies in which immune complex formation may contribute to the development of paraneoplastic syndromes.
  • novel anti-KSSKC antibodies of the invention allow the use of even lower dosage levels to treat GN and other inflammatory conditions. Based upon their level of activity in human blood, they are expected to provide complete complement inhibition at dosages below 0.005g/kg, and to provide therapeutically effective complement inhibition at dosages below-0.003g/kg. This 3mg/kg dosage is one tenth the dosage discussed below in Examples 4 and 5 for the for the anti-C5 (beta chain specific) mAb N19/8. Some of the full length anti-KSSKC mabs of the invention will provide therapeutic benefits even at dosages below 0.0022g/kg. This is the minimum dose providing complete complement inhibition as calculated from the data obtained using the anti-KSSKC 5G1.1 mAb in human blood in a CPB circuit, as discussed below in Example 9.
  • antibodies that do not bind to sites within the alpha chain of C5, and antibodies that bind to the C5 cleavage product C5a (free C5a), are believed to lack the ability to substantially block both complement hemolytic activity and the generation of C5a to substantially the same extent at the same concentration of antibody.
  • the antibodies preferably should prevent the cleavage of C5 to form C5a and C5b, thus preventing the generation of the anaphylatoxic activity associated with C5a and preventing the assembly of the membrane attack complex associated with C5b.
  • these anti-C5 antibodies will not impair the opsonization function associated with the activation of complement component C3 by a C3 convertase.
  • Plasma C3 convertase activity can be measured by assaying plasma for the presence of C3a as described below under the heading "Histology.”
  • the anti-C5 antibody produces essentially no reduction in plasma C3a levels.
  • cleavage site peptide i.e., the peptide spanning amino acids 725 through 754 of SEQ ID NO:2 (the C5a cleavage site), as discussed below in Example 13.
  • the transcriptional and translational control sequences in mammalian expression vector systems to be used in transforming vertebrate cells may be provided by viral sources.
  • viral sources for example, commonly used promoters and enhancers are derived from Polyoma virus, Adenovirus, Simian Virus 40 (SV40), and human cytomegalovirus, including the cytomegalovirus immediate-early gene 1 promoter and enhancer (CMV).
  • promoters and enhancers are derived from Polyoma virus, Adenovirus, Simian Virus 40 (SV40), and human cytomegalovirus, including the cytomegalovirus immediate-early gene 1 promoter and enhancer (CMV).
  • SV40 Simian Virus 40
  • CMV cytomegalovirus immediate-early gene 1 promoter and enhancer
  • the cells are washed 2x with GVBS and 5x10 6 cells are resuspended to 30 ⁇ L in GVBS. A 100 ⁇ L volume of serum test solution is then added to yield a final reaction mixture volume of 130 ⁇ L. As used herein, reference to the serum percentage and/or serum input in these assays indicates the percent serum in the 100 ⁇ L volume of serum test solution.
  • RNA For first strand cDNA synthesis, ten micrograms total RNA were denatured at 65°C for 5 min., chilled on ice, and added to a 100 ⁇ l reaction containing 10 mM Tris pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 10 mM dithiothreitol, 250 ⁇ M each dNTP, 20 units AMV reverse transcriptase (Seikagaku America, Rockville, MD), and 1.0 pmole of the appropriate 3' primer (as described in the Ig-PRIMER SET kit protocol).
  • Plasmid DNA was purified from cultures of transformed bacteria by conventional methods including column chromatography using a QUIAGEN-TIP-500 column according to the manufacturer's directions (Quiagen, Chatsworth, CA) and sequenced by the Sanger dideoxy chain termination method using SEQUENASE enzyme (U.S. Biochemical, Cleveland, OH). Clones obtained from a second independent PCR reaction verified that no mutations were introduced during the amplification process. The resulting plasmid containing the cloned variable region was designated SK (+) 690/395. This light chain encoding insert in this plasmid coded for both the N-terminal and internal light chain sequences determined by amino acid sequencing of 5G1.1, as described above.
  • Putative lambdaDE3 lysogens were grown in L broth supplemented with 0.2 % maltose and 10 mM MgSO 4 at 37°C to a cell density of approximately 10 8 cells/ml. A total of 0.5 ml of cells was centrifuged and the pellet was resuspended in 0.2 ml of a T7 phage lysate containing 2 x 10 4 pfu. The phage was allowed to adsorb for 30 min at 37°C. One-half of suspension (0.1 ml) was added to 3.0 ml of molten top agarose at 47°C and poured onto L plates. The remaining aliquot of cell/phage suspension was poured onto an L plate supplemented with 0.4 mM IPTG to check for induction of T7 RNA polymerase. The plates were inverted and incubated at 37°C overnight.
  • Tryptic digestion Twenty micrograms of purified human C5 (Advanced Technologies, San Diego, CA) was subjected to enzymatic digestion with 1 ⁇ g of TPCK-treated trypsin (Worthington Biochemical Corp., Freehold, NJ). The digestion was allowed to continue for 3 minutes, after which time it was stopped by the addition of 20 ⁇ g soy bean trypsin inhibitor (Worthington). The reaction was then denatured and reduced by the addition of protein sample buffer and immediately boiled for 5 min. The digested fragments were size fractionated through a SDS-PAGE on a 12 % gel.
  • Post-translational modifications can alter the mobility of proteins during SDS-PAGE electrophoresis.
  • One such modification is the addition of carbohydrate via N-linked glycosylation.
  • C5 is glycosylated, as is C5a.
  • C5a is glycosylated at an asparagine residue corresponding to amino acid number 723 of the full length pro-C5 precursor of human C5 (SEQ ID NO:2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10185086A 1994-05-02 1995-05-01 Antikörper gegen C5 und deren therapeutischen Verwendungen Withdrawn EP2298808A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/236,208 US6074642A (en) 1994-05-02 1994-05-02 Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP09008262A EP2112165A3 (de) 1994-05-02 1995-05-01 Verfahren und Zusammensetzungen zur Behandlung von Glomerulonephritis und anderen Entzündungskrankheiten
EP95919041A EP0758904B1 (de) 1994-05-02 1995-05-01 Methoden und zusammensetzungen für die behandlung von glomerulonephritis

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP95919041.4 Division 1995-11-09
EP09008262.9 Division 2009-06-24

Publications (1)

Publication Number Publication Date
EP2298808A1 true EP2298808A1 (de) 2011-03-23

Family

ID=22888581

Family Applications (5)

Application Number Title Priority Date Filing Date
EP95919041A Expired - Lifetime EP0758904B1 (de) 1994-05-02 1995-05-01 Methoden und zusammensetzungen für die behandlung von glomerulonephritis
EP10185083A Withdrawn EP2270046A3 (de) 1994-05-02 1995-05-01 Verfahren und Zusammensetzungen zur Behandlung von mit Hämolyse assoziierten Krankheiten
EP10185141A Withdrawn EP2270047A3 (de) 1994-05-02 1995-05-01 Antikörper gegen C5 und deren therapeutischen Verwendungen
EP09008262A Withdrawn EP2112165A3 (de) 1994-05-02 1995-05-01 Verfahren und Zusammensetzungen zur Behandlung von Glomerulonephritis und anderen Entzündungskrankheiten
EP10185086A Withdrawn EP2298808A1 (de) 1994-05-02 1995-05-01 Antikörper gegen C5 und deren therapeutischen Verwendungen

Family Applications Before (4)

Application Number Title Priority Date Filing Date
EP95919041A Expired - Lifetime EP0758904B1 (de) 1994-05-02 1995-05-01 Methoden und zusammensetzungen für die behandlung von glomerulonephritis
EP10185083A Withdrawn EP2270046A3 (de) 1994-05-02 1995-05-01 Verfahren und Zusammensetzungen zur Behandlung von mit Hämolyse assoziierten Krankheiten
EP10185141A Withdrawn EP2270047A3 (de) 1994-05-02 1995-05-01 Antikörper gegen C5 und deren therapeutischen Verwendungen
EP09008262A Withdrawn EP2112165A3 (de) 1994-05-02 1995-05-01 Verfahren und Zusammensetzungen zur Behandlung von Glomerulonephritis und anderen Entzündungskrankheiten

Country Status (15)

Country Link
US (2) US6074642A (de)
EP (5) EP0758904B1 (de)
JP (5) JP3734266B2 (de)
KR (2) KR100381128B1 (de)
AT (1) ATE448791T1 (de)
AU (1) AU2474795A (de)
BR (1) BR9507594B8 (de)
CA (2) CA2690298A1 (de)
DE (2) DE69536017D1 (de)
DK (1) DK0758904T3 (de)
ES (1) ES2336051T3 (de)
FR (1) FR10C0016I2 (de)
NL (1) NL300433I2 (de)
PT (1) PT758904E (de)
WO (1) WO1995029697A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023972A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Families Citing this family (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
DE69534701T2 (de) * 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
JP4437192B2 (ja) 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
US7112327B2 (en) 1998-02-20 2006-09-26 Tanox, Inc. Inhibition of complement activation
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
JP2003504019A (ja) * 1999-06-29 2003-02-04 オートゲン リサーチ プロプライエトリー リミティッド 肥満、糖尿病及びエネルギー不均衡の調節における新規な遺伝子及びそれらの使用
JP4764590B2 (ja) 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
EP2896631A1 (de) * 2000-10-10 2015-07-22 Genentech, Inc. Hemmung der Komplement-C5-Aktivierung zur Behandlung und Vorbeugung einer verzögerten Xenotransplantatabstoßung oder eines akuten Gefäßversagens
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
US20030109714A1 (en) * 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
WO2003009803A2 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals Inc. Method of improving cognitive function
EP3372243A1 (de) 2001-08-17 2018-09-12 Genentech, Inc. Komplement-inhibitoren, die an c5 und c5a binden, ohne die bildung von c5b zu hemmen
ES2283594T5 (es) * 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
AU2002359568B2 (en) 2001-12-03 2008-02-21 Alexion Pharmaceuticals, Inc. Hybrid antibodies
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2003081206A2 (en) * 2002-03-18 2003-10-02 Alexion Pharmaceuticals, Inc. Stratification of patient populations having or suspected of having rheumatoid arthritis
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
EP1718674A4 (de) * 2004-01-28 2008-05-07 Anil K Chauhan Mit im blutkreislauf befindlichen immunkomplexen assoziierte membran-attacke-komplexe
US20070116710A1 (en) * 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
EP2338511A3 (de) * 2004-05-14 2012-07-25 Alexion Pharmaceuticals, Inc. Verlängerung der Überlebungszeit eines Allografts durch Hemmung der Komplementsaktivität
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
EP1934867A2 (de) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
JP5722524B2 (ja) 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
NZ571791A (en) 2006-03-08 2012-03-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
WO2007130031A1 (en) * 2006-05-01 2007-11-15 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
EP2073898A1 (de) * 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Komplementhemmung für verbesserte nervenregeneration
WO2008048689A2 (en) * 2006-10-20 2008-04-24 Alexion Pharmaceuticals, Inc. Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
RU2325651C1 (ru) * 2006-12-22 2008-05-27 ФГУ "Российский научно-исследовательский институт геронтологии Росздрава" Способ диагностики гломерулонефрита
US20090081659A1 (en) 2007-03-07 2009-03-26 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
AU2008228247A1 (en) * 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US20090068684A1 (en) * 2007-03-26 2009-03-12 Cell Signaling Technology, Inc. Serine and threoninephosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
EP2145902A3 (de) 2007-04-19 2010-09-29 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
CA2696164C (en) * 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
JP5769968B2 (ja) 2007-10-18 2015-08-26 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
US20090203043A1 (en) 2007-11-21 2009-08-13 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
US20220281964A1 (en) * 2008-02-25 2022-09-08 Xencor, Inc. Fc VARIANTS WITH ALTERED BINDING TO FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP3023502A1 (de) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP2011519373A (ja) * 2008-05-01 2011-07-07 コンプレクザ インコーポレイテッド ビニル置換脂肪酸
US8148088B2 (en) * 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
ES2475199T3 (es) * 2008-09-16 2014-07-10 Imuneks Farma Ila� Sanayi Ve Ticaret A.S. Uso de antagonistas opioides para la preparación de un medicamento en el tratamiento de enfermedades degenerativas de la retina
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP3266795A1 (de) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Verfahren zum detektieren von fig-ros-fusionspolynukleotid
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
JP2012518408A (ja) 2009-02-24 2012-08-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体
US20100248265A1 (en) * 2009-02-27 2010-09-30 The Salk Institute For Biological Studies Compositions and methods for diagnosis and treatment of cancer
CA2766565A1 (en) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
EP2482816B8 (de) * 2009-10-01 2016-12-14 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Topische naltrexon-zusammensetzungen zur behandlung von hauterkrankungen
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
ES2615732T3 (es) * 2010-03-01 2017-06-08 Alexion Pharmaceuticals, Inc. Composiciones para tratar la enfermedad de Degos
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
BR112012027917A2 (pt) * 2010-04-30 2017-11-28 Alexion Pharma Inc anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano
MX340696B (es) 2010-04-30 2016-07-21 Alexion Pharma Inc Anticuerpos anti-c5a y metodos para usar los anticuerpos.
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
EP2625189B1 (de) 2010-10-01 2018-06-27 ModernaTX, Inc. Manipulierte nukleinsäuren und anwendungsverfahren dafür
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
EP2468295A1 (de) 2010-12-21 2012-06-27 Affiris AG Impfstoffe basierend auf Komplementprotein C5a Peptide
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR101648960B1 (ko) 2011-04-15 2016-08-22 서울대학교산학협력단 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도
EP3524258B1 (de) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Verfahren zur behandlung chronischer erkrankungen mit komplementinhibitoren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
KR20230143201A (ko) 2011-11-30 2023-10-11 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
SG11201404751UA (en) 2012-02-09 2014-09-26 Chugai Pharmaceutical Co Ltd Modified fc region of antibody
EP3511339B1 (de) 2012-02-20 2025-04-09 IPC Research, LLC An die menschliche komplementkomponente c5 bindende polypeptide
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
MX357540B (es) 2012-04-06 2018-07-13 Omeros Corp Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de la hemoglobinuria paroxistica nocturna.
PL2838998T3 (pl) 2012-04-18 2018-04-30 Cell Signaling Technology, Inc. EGFR i ROS1 w nowotworze
BR112014031522A2 (pt) 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2014119969A1 (ko) * 2013-01-31 2014-08-07 서울대학교 산학협력단 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법
PE20151893A1 (es) 2013-03-14 2015-12-30 Parkash Gill Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular
IL288931B2 (en) 2013-03-14 2025-05-01 Alnylam Pharmaceuticals Inc Compositions comprising a complementary portion of C5 IRNA and methods of using them
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2978451B1 (de) 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur erhöhung der serumhalbwertzeit eines therapeutisches mittel gegen komplement-c5
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
BR112016003142A2 (pt) 2013-08-28 2017-10-17 Swedish Orphan Biovitrum Ab Publ ligação de polipeptídeos estáveis ao c5 do complemento humano
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
US20150104445A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
SG10201804960RA (en) 2013-12-12 2018-07-30 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3102701A1 (de) 2014-02-07 2016-12-14 Novartis AG Auswirkung von genetische faktoren auf die krankheitsprogression und reaktion auf anti-c5-antikörper bei geografischer atrophie
WO2015127134A2 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US9732103B2 (en) 2014-02-25 2017-08-15 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
ES2824262T3 (es) * 2014-02-26 2021-05-11 Allergan Inc Anticuerpos contra componente C5 del complemento
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
EP3636073B1 (de) 2014-05-05 2023-11-15 Regeneron Pharmaceuticals, Inc. Humanisierte c5- und c3-tiere
EP3973994A1 (de) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation der komplementaktivität
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
JP6948942B2 (ja) 2014-10-15 2021-10-13 アレクシオン ファーマシューティカルズ， インコーポレイテッド タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
WO2016061066A1 (en) 2014-10-15 2016-04-21 Alexion Pharmaceuticals, Inc. Methods of replicating a large scale eculizumab production cell culture
EP3207058A1 (de) 2014-10-15 2017-08-23 Alexion Pharmaceuticals, Inc. Verfahren zur kultivierung einer zelle
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN113956354A (zh) 2015-01-22 2022-01-21 中外制药株式会社 两种以上抗-c5抗体的组合与使用方法
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
TR201904903T4 (tr) 2015-03-25 2019-05-21 Alexion Pharma Inc Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem.
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US20180311299A1 (en) 2015-05-01 2018-11-01 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3313437A1 (de) * 2015-06-26 2018-05-02 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung eines patienten in übereinstimmung mit einer impfung mit eculizumab oder einer eculizumab-variante
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US20170073399A1 (en) 2015-09-11 2017-03-16 Alexion Pharmaceuticals, Inc. Recombinant glycosylated eculizumab and eculizumab variants
US20180243370A1 (en) 2015-09-14 2018-08-30 Children's Hospital Medical Center Methods and compositions for treatment of gaucher disease via modulation of c5a receptor
EP3359566A1 (de) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung altersbedingter makuladegeneration bei einem patienten
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3368090A1 (de) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-faktor-d-antikörpervarianten-konjugate und verwendungen davon
JP7221691B2 (ja) 2015-10-30 2023-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｔ細胞媒介性同種移植片血管障害の増悪を抑制する方法
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
HUE065073T2 (hu) 2015-12-18 2024-04-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
US20190127453A1 (en) 2016-06-07 2019-05-02 Novartis Ag An anti-c5 antibody dosing regimen
EP3469083A1 (de) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
IL263657B2 (en) 2016-06-17 2025-12-01 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
EP3494991A4 (de) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
WO2018071624A1 (en) 2016-10-12 2018-04-19 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
EP3529619B1 (de) 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. Verfahren zur quantifizierung von ungebundenem c5a in einer probe
WO2018075758A1 (en) 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
KR102365871B1 (ko) 2017-01-31 2022-02-21 추가이 세이야쿠 가부시키가이샤 C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
EP3589287B1 (de) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Makrocyclische verbindungen zur behandlung von medizinischen erkrankungen
SG11201908744PA (en) 2017-03-23 2019-10-30 Univ Pennsylvania Anti-c5a antibodies and uses thereof
ES2999550T3 (en) 2017-03-31 2025-02-26 Alexion Pharma Inc Method for simultaneous quantification of alxn1210 and eculizumab in human serum or urine
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
EP3612561A1 (de) 2017-04-19 2020-02-26 Alexion Pharmaceuticals, Inc. Wirksamkeit eines anti-c5-antikörpers bei der prävention einer antikörpervermittelten abstossung bei sensibilisierten empfängern eines nierentransplantats
US11730792B2 (en) * 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7194698B2 (ja) 2017-05-22 2022-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者においてタンパク質漏出性腸症を処置するための抗ｃ５抗体の投薬量および投与
DK3658184T5 (da) 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
EP3661493A4 (de) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. Therapiepläne zur behandlung von paroxysmaler nächtlicher hämoglobinurie
BR112020006692A2 (pt) 2017-10-04 2020-10-06 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para o tratamento de pacientes com glomerulonefrite membranoproliferativa
CN118512588A (zh) 2017-10-26 2024-08-20 亚力兄制药公司 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
MX2020004921A (es) 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
US12037389B2 (en) 2017-12-01 2024-07-16 Children's Hospital Medical Center Compositions for interferon blockade and methods of using same
CA3274059A1 (en) 2017-12-13 2026-03-02 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
EP3802593B1 (de) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosierung und verabreichung von anti-c5 antikörpern zur behandlung von paroxysalen nocturalen hämoglobin-uria (pnh) in pädiatrischen patienten
EP3802603A1 (de) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosierung und verabreichung von anti-c5-antikörpern zur behandlung des atypischen hämolytisch-urämischen syndroms (ahus) bei kindern
CN112654394B (zh) * 2018-06-19 2025-07-11 阿塔盖有限责任公司 针对补体成分5的抗体分子和其用途
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
MY210523A (en) 2018-08-01 2025-09-29 Univ Osaka A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
EP3852874A1 (de) 2018-09-17 2021-07-28 Kyoto University Verabreichung eines anti-c5-mittels zur behandlung von leberverletzungen oder -versagen
US20200095307A1 (en) 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica
KR20210093855A (ko) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 보체 인자 d 억제제의 형태체 형태
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
EP3873602B1 (de) 2018-10-30 2023-12-06 Alexion Pharmaceuticals, Inc. Subcutane dosierung und ztudienung von anti-c5-antikörpern zur behandlung der paroxysmalen nicht-turnalen hämoglobinurie (pnh)
US20220002393A1 (en) 2018-11-20 2022-01-06 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
US20220017899A1 (en) 2018-11-23 2022-01-20 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
EP3730617A1 (de) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nukleinsäure zur hemmung der expression von c3 in einer zelle
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
WO2020131974A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
CN117838856A (zh) 2019-01-25 2024-04-09 亚力兄制药公司 用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用
BR112021018456A2 (pt) 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
US20220227851A1 (en) 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
KR20240033090A (ko) 2019-07-31 2024-03-12 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
CR20220040A (es) 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab
US20220259305A1 (en) 2019-08-05 2022-08-18 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
BR112022003513A2 (pt) 2019-08-27 2022-05-17 Silence Therapeutics Gmbh Ácidos nucleicos para inibição da expressão de c3 em uma célula
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
KR20220110827A (ko) 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 시신경척수염 스펙트럼 장애의 치료를 위한 항-c5 항체
JP7734673B2 (ja) 2019-12-23 2025-09-05 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃ５抗体を使用して妊娠関連非典型溶血性尿毒症症候群を治療する方法
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
CN115362162A (zh) 2020-02-20 2022-11-18 艾其林医药公司 用于治疗补体因子d介导的障碍的杂芳基化合物
EP4114947A1 (de) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
PH12022552556A1 (en) 2020-03-27 2024-04-22 Inflarx Gmbh Inhibitors of c5a for the treatment of corona virus infection
EP4135837A1 (de) 2020-04-16 2023-02-22 Assistance Publique, Hopitaux De Paris Verfahren zur behandlung einer komplementvermittelten virusbedingten erkrankung
JP2023523790A (ja) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体因子Ｂ（ＣＦＢ）ｉＲＮＡ組成物およびその使用方法
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗ｃ５ａ抗體
US20230172930A1 (en) 2020-05-12 2023-06-08 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
EP4161653A1 (de) 2020-06-03 2023-04-12 Bionecure Therapeutics, Inc. Trophoblastzelloberflächenantigen-2 (trop-2)-antikörper
KR102836238B1 (ko) 2020-06-16 2025-07-18 에프. 호프만-라 로슈 아게 샘플에서 항체의 유리 항원 측정 방법
CA3173011A1 (en) 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
JP7494413B2 (ja) * 2020-07-15 2024-06-04 ビオシオン インコーポレイテッド Ｃ５に結合する抗体及びその用途
CN116437913A (zh) 2020-09-23 2023-07-14 艾其林医药公司 用于治疗补体介导的病症的药物化合物
US20230391863A1 (en) 2020-10-23 2023-12-07 Hq Han Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof
EP4274896A1 (de) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Komplementkomponente 9 (c9)-irna-zusammensetzungen und verfahren zur verwendung davon
US20240101717A1 (en) 2021-01-22 2024-03-28 Bionecure Therapeutics, Inc. Anti-her-2/trop-2 constructs and uses thereof
EP4281472A1 (de) 2021-01-22 2023-11-29 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von komplementvermittelter thrombotischer mikroangiopathie unter verwendung eines anti-c5-antikörpers
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
WO2022251446A1 (en) 2021-05-28 2022-12-01 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
WO2023031359A1 (en) 2021-09-02 2023-03-09 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
US20230203176A1 (en) 2021-09-17 2023-06-29 Novartis Ag Methods For Prevention Of Graft Rejection In Xenotransplantation
JP2024535850A (ja) 2021-09-17 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
CN118302525A (zh) 2021-10-29 2024-07-05 阿尔尼拉姆医药品有限公司 补体因子B（CFB）iRNA组合物及其使用方法
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
EP0411306A1 (de) 1989-07-27 1991-02-06 Götze, Otto Prof. Dr. med. Verfahren zum Nachweis und/oder der quantitativen Bestimmung von Komplementpeptid C5a und/oder C5adesarg
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
US4845198A (en) 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US4816565A (en) 1985-08-13 1989-03-28 Tasuku Honjo Interleukin 2 receptor and a method for production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
FR2671350A1 (fr) 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
GB9120467D0 (en) * 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
EP0619324B1 (de) * 1991-12-20 2002-07-03 Yamanouchi Pharmaceutical Co. Ltd. Mit gp11b/iiia reaktive humane antikörper
DE69328098T2 (de) * 1992-06-24 2000-08-24 Adprotech Plc, Royston Lösliche derivate des complement type-rezeptors (cr1)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
EP0411306A1 (de) 1989-07-27 1991-02-06 Götze, Otto Prof. Dr. med. Verfahren zum Nachweis und/oder der quantitativen Bestimmung von Komplementpeptid C5a und/oder C5adesarg

Non-Patent Citations (94)

* Cited by examiner, † Cited by third party
Title
"Antibodies, A Laboratorv Manual", 1988, COLD SPRING HARBOR LABORATORY
"Antibody Engineering, A Practical Guide", 1992, W.H. FREEMAN AND CO.
"Current Protocols In Immunolocxv", 1992, JOHN WILEY & SONS
"Current Protocols In Immunology", 1992, JOHN WILEY & SONS
"Current Protocols in Immunology", 1992, JOHN WILEY & SONS, pages: 2.5.1,2.
"Reminaton's Pharmaceutical Sciences, 17th ed;", 1985, MACK PUBLISHING COMPANY
AMERICAN TYPE CULTURE COLLECTION, 27 April 1994 (1994-04-27), pages 20852
AMES ET AL., J. IMMUNOL., vol. 152, 1994, pages 4572 - 4581
AMMERER, METH. ENZYMOL., vol. 101, 1983, pages 192
B. MORGAN: "Clinical complementology: Recent progress and future trends.", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 24, no. 4, April 1994 (1994-04-01), GB, pages 219 - 228, XP008040182 *
BAKER ET AL., AMERICAN JOURNAL OF PATHOLOCRV., vol. 135, 1989, pages 185 - 194
BORREBAEK: "Antibody Engineering,2nd ed.", 1995, OXFORD UNIVERSITY PRESS
CHANG ET AL., NATURE, vol. 275, pages 615
CHOMCZYNSKI; SACCHI, ANAL. BIOCHEM., vol. 162, 1987, pages 156 - 159
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
COCHRANE ET AL., JOURNAL OF EXPERIMENTAL MEDICINE, vol. 122, 1965, pages 99 - 116
COLIGAN, ET AL.,: "Current Protocols in Immunology", 1992, JOHN WILEY & SONS
COUSER ET AL., JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 2, 1991, pages 894 - 901
COUSER ET AL., KIDNEV INTERNATIONAL., vol. 28, 1985, pages 897 - 890
COUSER ET AL., NEPHROLOGY DIALVSIS TRANSPLANTATION., vol. 1, 1992, pages 25 - 30
COUSER, KIDNEV INTERNATIONAL., vol. 44, no. 42, 1993, pages S19 - S26
COUSER: "Cecil Textbook of Medicine,19th Ed.", vol. 79, 1992, W.B. SAUNDERS CO., pages: 551 - 568
DAMERAU ET AL., MOLEC. IMMUNOL., vol. 26, 1989, pages 1133 - 1142
DIXON ET AL.: "Immunological Diseases,4th ed.", 1987, LITTLE BROWN & CO, article "Immune Complex Iniurv"
EVANS; SCARPULLA, GENE, vol. 84, 1989, pages 135
FALK; JENNETTE, KIDNEV INTERNATIONAL., vol. 30, 1986, pages 678 - 686
FEARON: "Brigham and Women's and Beth Israel Hospitals, 2nd Ed.", 1983, article "Intensive Review of Internal Medicine"
FEARON: "Intensive Review of Internal Medicine.. 2nd; Ed.", 1983, BRIGHAM AND WOMEN'S AND BETH ISRAEL HOSPITALS, pages: 204 - 210
FLOEGE ET AL., LABORATORV INVESTIAATION, vol. 67, 1992, pages 486 - 497
FREI ET AL., MOLECULAR AND CELLULAR PROBES, vol. 1, 1987, pages 141 - 149
FRIGUET ET AL., J. IMMUNOL. METH., vol. 77, 1985, pages 305 - 319
GICLAS ET AL., J. IMMUNOL. METH., vol. 105, 1987, pages 201 - 209
GLASSOCK; BRENNER: "Harrison's Principles of Internal Medicine, 11th Ed.", 1987, MCGRAW-HILL BOOKCO., pages: 1170 - 1189
GLASSOCK; BRENNER: "Harrison's Principles of Internal Medicine, 13th Ed.", 1994, MCGRAW-HILL, INC., pages: 1292 - 1313
GOEDDEL ET AL.: "Gene Expression Technology", vol. 185, 1980, ACADEMIC PRESS, INC.
GREEN ET AL., NATURE GENET., vol. 7, 1994, pages 13 - 21
GROGGEL ET AL., JOURNAL OF CLINICAL INVESTIGATIONS, 1983
GUYTON: "Textbook of Medical Physiology. 4th Ed.", 1971, W.B. SAUNDERS CO., pages: 393 - 405,442-
HABER, IMMUNOL REV, vol. 130, 1992, pages 189 - 212
HABER, IMMUNOLOCRV REVIEW, vol. 130, 1992, pages 189 - 212
HARLOW; LANE: "Antibodies, A Laboratory Manual.", 1988, COLD SPRING HARBOR LABORATORY
HARLOW; LANE: "Antibodies. A Laboratorv Manual", 1988, COLD SPRING HARBOR LABORATORY
HAVILAND ET AL., J. IMMUNOL., vol. 146, 1991, pages 362 - 368
HIETER ET AL., CELL, vol. 22, 1980, pages 197 - 207
HUANG; GORMAN, MOLEC. CELL BIOL., vol. 10, 1990, pages 1805
J. MOL. BIOL., vol. 196, 1987, pages 901
JENNETTE ET AL., AMERICAN JOURNAL OF PATHOLOCRV., vol. 127, 1987, pages 499 - 506
JOHNE ET AL., J. IMMUNOL. METH., vol. 160, 1993, pages 191 - 198
KABAT ET AL.: "Sequences of Proteins of Immunological Interest,4th ed.", PUBLIC HEALTH SERVICE, N.I.H.
KAY ET AL., GENE, vol. 128, 1993, pages 59 - 65
KNICKER; COCHRANE, JOURNAL OF EXPERIMENTAL MEDICINE, vol. 122, 1965, pages 83 - 98
LIDDELL; CRYER: "A Practical Guide to Monoclonal _ Antibodies", 1991, JOHN WILEY & SONS
LIDDELL; CRYER: "A Practical Guide To Monoclonal Antibodies", 1991, JOHN WILEY & SONS
MANIATIS: "Molecular Cloning: A Laboratory Manual", 1982, COLD SPRING HARBOR LABORATORY
MINTA; MAN, J. IMMUNOL., vol. 119, 1977, pages 1597 - 1602
MOIR ET AL., METH. ENZYMOL., vol. 194, 1991, pages 491 - 507
MOLLNES ET AL., SCAND. J. IMMUNOL., vol. 28, 1988, pages 307 - 312
MOLLNES ET AL., SCANDINAVIAN JOURNAL OF IMMUNOLOAV., vol. 28, 1988, pages 307 - 312
MONTZ ET AL., CELLULAR IMMUNOL., vol. 127, 1990, pages 337 - 351
MONTZ ET AL., CELLULAR IMMUNOLOCRV., vol. 127, 1990, pages 337 - 351
MOONGKARNDI ET AL., IMMUNOBIOL, vol. 162, 1982, pages 397
MOONGKARNDI ET AL., IMMUNOBIOL, vol. 165, 1983, pages 323
MOONGKARNDI ET AL., IMMUNOBIOL., vol. 162, 1982, pages 397
MOONGKARNDI ET AL., IMMUNOBIOL., vol. 165, 1983, pages 323
MORGENSTERN; LAND, NUCLEIC ACIDS RES., vol. 18, 1990, pages 3587 - 3596
MORRISON ET AL., ANNUAL REVIEW OF IMMUNOLOGY, vol. 10, 1992, pages 239 - 265
MORRISON, ANNU REV IMMUNOL, vol. 10, 1992, pages 239 - 265
P. GICLAS ET AL.: "Preparation and characterization of monoclonal antibodies against the fifth component of rabbit complement (C5).", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 105, no. 2, 24 December 1987 (1987-12-24), pages 201 - 209, XP023973513 *
PASSWELL ET AL., THE AMERICAN SOCIETV FOR CLINICAL _ INVESTIGATION. INC., vol. 82, 1988, pages 1676 - 1684
PROUDFOOT ET AL., PROTEIN EXPRESS. PURIF., vol. 3, 1992, pages 368
R. WÜRZNER ET AL.: "Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.", COMPLEMENT AND INFLAMMATION, vol. 8, no. 5-6, 1991, BASEL, SWITZERLAND, pages 328 - 340, XP000940579 *
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327
RICH: "Cecil Textbook of Medicine, 19th Ed.", vol. 249, 1992, W.B. SAUNDERS CO., pages: 1467 - 1470
ROBBINS; COTRAN: "Patholoaic Basis of Disease, 2nd _ ed.", 1979, W.B. SAUNDERS CO., pages: 1128 - 1129
RODRIGUES ET AL., J IMMUNOL, vol. 151, 1993, pages 6954 - 6961
RODRIGUES ET AL., JOURNAL OF IMMUNOLOGY, vol. 151, 1993, pages 6954 - 6961
ROLLINS ET AL., J IMMUNOL, vol. 144, 1990, pages 3478 - 3483
S. MORRISON: "In vitro antibodies: Strategies for production and application.", ANNUAL REVIEW OF IMMUNOLOGY, vol. 10, 1992, USA, pages 239 - 265, XP000983246 *
SALANT ET AL., JOURNAL OF CLINICAL INVESTIGATIONS., vol. 66, 1980, pages 1339 - 1350
SATO ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 17267
SCHENA ET AL., METH. ENZYMOL., vol. 194, 1991, pages 389 - 398
SCHRIJVER ET AL., KIDNEV INTERNATIONAL., vol. 38, 1990, pages 86 - 95
SCHRIJVER ET AL., LABORATORV INVESTIGATION., vol. 59, 1988, pages 484 - 491
SEIDMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 75, 1978, pages 3881 - 3885
SMITH; SCOTT, METH. ENZYMOL., vol. 217, 1993, pages 228
STUDIER ET AL., METH. ENZYMOL., vol. 185, 1990, pages 60 - 89
STUDIER, METH. ENZYMOL., vol. 185, 1990, pages 60 - 89
UNANUE; DIXON, JOURNAL OF EXPERIMENTAL MEDICINE, vol. 119, 1964, pages 965 - 982
WETSEL; KOLB, J. IMMUNOL., vol. 128, 1982, pages 2209 - 2216
WINTER; MILSTEIN, NATURE, vol. 349, 1991, pages 293 - 299
WURZNER ET AL., COMNLEMENT INFLAMM., vol. 8, 1991, pages 328 - 340
WURZNER ET AL., COMPLEMENT INFLAMM, vol. 8, 1991, pages 328 - 340
WURZNER ET AL., COMPLEMENT INFLAMMATION., vol. 8, 1991, pages 328 - 340
YAMMAMOTO; GEWURZ, J. IMMUNOL., vol. 120, 1978, pages 2008

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023972A1 (en) * 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant

Also Published As

Publication number Publication date
FR10C0016I1 (de) 2010-04-30
EP0758904A4 (de) 2005-04-20
NL300433I2 (en) 2010-04-01
EP2270046A2 (de) 2011-01-05
AU2474795A (en) 1995-11-29
NL300433I1 (en) 2010-03-01
EP2112165A3 (de) 2011-03-23
JPH10500289A (ja) 1998-01-13
JP2009165471A (ja) 2009-07-30
EP2270046A3 (de) 2011-03-23
EP2270047A3 (de) 2011-03-23
EP0758904B1 (de) 2009-11-18
DK0758904T3 (da) 2010-01-18
EP2270047A2 (de) 2011-01-05
JP2005185286A (ja) 2005-07-14
ATE448791T1 (de) 2009-12-15
WO1995029697A1 (en) 1995-11-09
BR9507594B1 (pt) 2010-08-10
BR9507594B8 (pt) 2015-06-02
US6355245B1 (en) 2002-03-12
DE69536017D1 (de) 2009-12-31
CA2189015A1 (en) 1995-11-09
DE122009000075I1 (de) 2010-05-12
KR100442019B1 (ko) 2004-07-30
EP2112165A2 (de) 2009-10-28
FR10C0016I2 (fr) 2011-04-01
JP5047996B2 (ja) 2012-10-10
JP2012095650A (ja) 2012-05-24
EP0758904A1 (de) 1997-02-26
JP4294596B2 (ja) 2009-07-15
KR20040000388A (ko) 2004-01-03
ES2336051T3 (es) 2010-04-07
JP2006020633A (ja) 2006-01-26
JP3734266B2 (ja) 2006-01-11
BR9507594A (pt) 1997-09-16
CA2189015C (en) 2010-04-13
US6074642A (en) 2000-06-13
PT758904E (pt) 2010-02-10
KR100381128B1 (ko) 2003-09-29
CA2690298A1 (en) 1995-11-09

Similar Documents

Publication Publication Date Title
EP0758904B1 (de) Methoden und zusammensetzungen für die behandlung von glomerulonephritis
RU2760582C2 (ru) Анти-LAG-3 антитела
EP2033659B1 (de) Hemmer der Komplementaktivierung
RU2112037C1 (ru) Гибридное моноклональное антитело, взаимодействующее с cd4-антигеном т-хелперных клеток человека, и способ его получения
CA2103887C (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2288992C (en) Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
JP2020031650A (ja) 補体関連疾患の予防及び治療のためのｃ５抗体及び方法
AU9413898A (en) Receptor on the surface of activated T-cells: ACTS-4
JP2023537422A (ja) Ｉｌ－１１の抗体及びその使用
EP1140171A1 (de) Methoden und produkte zur regulation der, mit dem lectin-komplementsystem assoziierten, komplementaktivierung
CN111116743A (zh) Hsp90抗体及其在抗真菌感染中的应用
RU2741802C2 (ru) АНТИТЕЛО К Myl9
HK1154028A (en) Anti-c5 antibodies and their therapeutic uses
HK1133666A (en) Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
HK1148539A (en) Methods and compositions for the treatment of hemolysis-associated diseases
HK1148540A (en) Anti-c5 antibodies and their therapeutic uses
US20230355672A1 (en) Humanized antigen binding units for targeting osteosarcoma cells
CN119798438B (zh) 一种抗ccr8单克隆抗体及其应用
JPWO2007023782A1 (ja) キラートキシン様タンパク質に対する中和抗体、およびその利用
WO2025096903A1 (en) Anti-c2 binding agents and conjugates thereof
JP2024105575A (ja) 特定の腸内細菌の抗体媒介中和による免疫疾患の治療
CN118085083A (zh) 一种小鼠抗人fam19a4单克隆抗体及其用途
JPWO2006093071A1 (ja) βグルカン合成酵素を有する真菌に対して抗真菌活性を有する抗イディオタイプ抗体、およびその利用
NO316023B1 (no) Fremgangsmåte for fremstilling av et terapeutisk aktivt antistoff eller etterapeutisk aktivt fragment derav som er selektive for TAG-72

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 0758904

Country of ref document: EP

Kind code of ref document: P

Ref document number: 2112165

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 20110920

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110924

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154028

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154028

Country of ref document: HK